MEDtalk: What are the key clinical messages from the SPARTAN study?

Best Practice Nordic | Jun 2020 | ASCO20 Virtual |

In this MEDtalk, Professor Eric J. Small talks about to which extent patients with non-metastatic castration-resistant prostate cancer achieve metastasis-free survival, and whether it is possible to delay the time to chemotherapy use. He also discusses the impact on overall survival.